Literature DB >> 23336515

Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells.

Shengpeng Wang1, Zhangfeng Zhong, Jianbo Wan, Wen Tan, Guosheng Wu, Meiwan Chen, Yitao Wang.   

Abstract

Oridonin, a natural tetracycline diterpenoid isolated from Chinese herb Rabdosia rubescens, has been reported to be a potent cytotoxic agent against a wide variety of tumors. However, its effect on highly metastatic breast cancer cells has not been addressed. In this study, we investigated the effects of oridonin on growth, migration and invasion of highly-metastatic human breast cancer cells. Our results showed that oridonin induced potent growth inhibition on human breast cancer cells MCF-7 and MDA-MB-231 in a time- and dose-dependent manner. According to the flow cytometric analysis, oridonin suppressed MCF-7 cell growth by cell cycle arrest at the G2/M phase and caused accumulation of MDA-MB-231 cells in the Sub-G1 phase. The induced apoptotic effect of oridonin was further confirmed by a morphologic characteristics assay and TUNEL assay. Oridonin triggered the reduction of Bcl-2/Bax ratio, caspase-8, NF-κB (p65), IKKα, IKKβ, phospho-mTOR, and increased expression level of cleaved PARP, Fas and PPARγ in a time-dependent manner. Immunofluorescent analysis showed that γH2AX-containing nuclear foci were significant in oridonin-treated MDA-MB-231 cells. Meanwhile, oridonin significantly suppressed MDA-MB-231 cell migration and invasion, decreased MMP-2/MMP-9 activation and inhibited the expression of Integrin β1 and FAK. In conclusion, oridonin inhibited the growth and induced apoptosis in breast cancer cells, which might be related to DNA damage and activation of intrinsic or extrinsic apoptotic pathways. Moreover, oridonin also inhibited tumor invasion and metastasis in vitro possibly via decreasing the expression of MMPs and regulating the Integrin β1/FAK pathway in MDA-MB-231 cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23336515     DOI: 10.1142/S0192415X13500134

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  33 in total

1.  Oridonin suppress cell migration via regulation of nonmuscle myosin IIA.

Authors:  Yin-Chao Li; Mo-Ran Sun; Yi-Hong Zhao; Xian-Zu Fu; Hai-Wei Xu; Ji-Feng Liu
Journal:  Cytotechnology       Date:  2014-10-09       Impact factor: 2.058

2.  Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl-2.

Authors:  Sirui Li; Dan Shi; Liangyu Zhang; Fang Yang; Guanghui Cheng
Journal:  Exp Ther Med       Date:  2018-09-27       Impact factor: 2.447

3.  Oridonin induces G2/M cell cycle arrest and apoptosis via the PI3K/Akt signaling pathway in hormone-independent prostate cancer cells.

Authors:  Jianlei Lu; Xiang Chen; Shuang Qu; Bing Yao; Yuexin Xu; Jiahui Wu; Yucui Jin; Changyan Ma
Journal:  Oncol Lett       Date:  2017-02-20       Impact factor: 2.967

4.  Oridonin alters the expression profiles of microRNAs in BxPC-3 human pancreatic cancer cells.

Authors:  Zhifang Gui; Shuquan Li; Xing Liu; Bin Xu; Jian Xu
Journal:  BMC Complement Altern Med       Date:  2015-04-14       Impact factor: 3.659

Review 5.  Molecular Insight in the Multifunctional Effects of Oridonin.

Authors:  Brice Ayissi Owona; Herman J Schluesener
Journal:  Drugs R D       Date:  2015-09

6.  Oridonin stabilizes retinoic acid receptor alpha through ROS-activated NF-κB signaling.

Authors:  Yang Cao; Wei Wei; Nan Zhang; Qing Yu; Wen-Bin Xu; Wen-Jun Yu; Guo-Qiang Chen; Ying-Li Wu; Hua Yan
Journal:  BMC Cancer       Date:  2015-04-10       Impact factor: 4.430

7.  Oridonin ameliorates inflammation-induced bone loss in mice via suppressing DC-STAMP expression.

Authors:  Bin-Hua Zou; Yan-Hui Tan; Wen-de Deng; Jie-Huang Zheng; Qin Yang; Min-Hong Ke; Zong-Bao Ding; Xiao-Juan Li
Journal:  Acta Pharmacol Sin       Date:  2020-08-04       Impact factor: 6.150

8.  Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway.

Authors:  Runfa Bao; Yijun Shu; Xiangsong Wu; Hao Weng; Qian Ding; Yang Cao; Maolan Li; Jiasheng Mu; Wenguang Wu; Qichen Ding; Zhujun Tan; Tianyu Liu; Lin Jiang; Yunping Hu; Jianfeng Gu; Yingbin Liu
Journal:  BMC Cancer       Date:  2014-03-21       Impact factor: 4.430

Review 9.  Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players.

Authors:  Shazia Ali; Neelima Mondal; Hani Choudhry; Mahmood Rasool; Peter N Pushparaj; Mohammad A Khan; Maryam Mahfooz; Ghufrana A Sami; Jummanah Jarullah; Ashraf Ali; Mohammad S Jamal
Journal:  Front Oncol       Date:  2016-03-01       Impact factor: 6.244

10.  Henrin A: A New Anti-HIV Ent-Kaurane Diterpene from Pteris henryi.

Authors:  Wan-Fei Li; Juan Wang; Jing-Jie Zhang; Xun Song; Chuen-Fai Ku; Juan Zou; Ji-Xin Li; Li-Jun Rong; Lu-Tai Pan; Hong-Jie Zhang
Journal:  Int J Mol Sci       Date:  2015-11-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.